Influenza A Virus, H3N2 Subtype Infections-Pipeline Review, H1 2017

Influenza A Virus, H3N2 Subtype Infections-Pipeline Review, H1 2017


  • Products Id :- GMDHC9089IDB
  • |
  • Pages: 113
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Influenza A Virus, H3N2 Subtype Infections-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Influenza A Virus, H3N2 Subtype Infections-Pipeline Review, H1 2017, provides an overview of the Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline landscape.

H3N2 infections are caused by variant H3N2 virus which is an influenza virus. Symptoms include cough, sore throat, runny or stuffy nose, chills, nausea, vomiting, and/or diarrhea. Risk factors include age, chronic medical conditions like asthma, diabetes, heart disease, weakened immune systems, and neurological or neurodevelopment conditions. Treatment includes antiviral medications and antibiotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Influenza A Virus, H3N2 Subtype Infections-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Influenza A Virus, H3N2 Subtype Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenza A Virus, H3N2 Subtype Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 6, 7, 5, 16 and 2 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I and Preclinical stages comprises 1, 1, 1 and 4 molecules, respectively.

Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Influenza A Virus, H3N2 Subtype Infections (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Influenza A Virus, H3N2 Subtype Infections (Infectious Disease)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Influenza A Virus, H3N2 Subtype Infections (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Influenza A Virus, H3N2 Subtype Infections-Overview

Influenza A Virus, H3N2 Subtype Infections-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Influenza A Virus, H3N2 Subtype Infections-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Influenza A Virus, H3N2 Subtype Infections-Companies Involved in Therapeutics Development

AbbVie Inc

AIMM Therapeutics BV

Aphios Corp

BiondVax Pharmaceuticals Ltd

Celltrion Inc

FluGen Inc

Glide Pharmaceutical Technologies Ltd

ILiAD Biotechnologies LLC

Inovio Pharmaceuticals Inc

Johnson & Johnson

Medicago Inc

MedImmune LLC

Mucosis BV

NanoViricides Inc

Novavax Inc

OPKO Health Inc

Protein Sciences Corp

Sanofi Pasteur SA

Sarepta Therapeutics Inc

SK Chemicals Co Ltd

Takeda Pharmaceutical Company Ltd

VBI Vaccines Inc

Visterra Inc

Zydus Cadila Healthcare Ltd

Influenza A Virus, H3N2 Subtype Infections-Drug Profiles

APP-0205-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

APP-309-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Aspidasept-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AV-5075S-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AV-5080-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cetylpyridinium chloride-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CR-8020-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CR-8043-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CTP-27-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fluad (quadrivalent)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FluGEM-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gamma-Flu-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H3N2] (monovalent) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H3N2] vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H3N2] vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H3N2] vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H3N2v] vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H3N2v] vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + A/H5N1] (virus like particle) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + A/H5N1] vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (quadrivalent) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent, virus like particle) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, split virion) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, virus like particle) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + B] (quadrivalent) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + B] (trivalent) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + B] vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JNJ-3872-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

M-001-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NBP-607-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NEO-8877-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NVINF-1-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NVINF-2-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptides for Influenza Infections-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pertussis [strain BPZE1] vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PNSIA-28-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

radavirsen-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

REDEE FLU-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for RSV and Influenza A Infections-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VIS-410-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Influenza A Virus, H3N2 Subtype Infections-Dormant Projects

Influenza A Virus, H3N2 Subtype Infections-Discontinued Products

Influenza A Virus, H3N2 Subtype Infections-Product Development Milestones

Featured News & Press Releases

Jan 12, 2017: Study Published in Vaccine Journal Indicates BiondVax's Universal Flu Vaccine Candidate May Cover Strains Which Don't Yet Exist

Jun 23, 2016: AstraZeneca provides update on Flumist Quadrivalent Vaccine in the US for the 2016-17 influenza season

Dec 21, 2012: Sarepta Therapeutics Enters Into Clinical Trial Agreement With NIH For Further Development Of Influenza Drug AVI-7100

Oct 09, 2012: NanoViricides's Oral FluCide Drug Candidate Found To Be Superior To Oseltamivir In Reduction Of Virus Load And Lung Damage Pathology In Animal Models With H3N2 Influenza

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development for Influenza A Virus, H3N2 Subtype Infections, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

List of Tables

Number of Products under Development for Influenza A Virus, H3N2 Subtype Infections, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Influenza A Virus, H3N2 Subtype Infections-Pipeline by AbbVie Inc, H1 2017

Influenza A Virus, H3N2 Subtype Infections-Pipeline by AIMM Therapeutics BV, H1 2017

Influenza A Virus, H3N2 Subtype Infections-Pipeline by Aphios Corp, H1 2017

Influenza A Virus, H3N2 Subtype Infections-Pipeline by BiondVax Pharmaceuticals Ltd, H1 2017

Influenza A Virus, H3N2 Subtype Infections-Pipeline by Celltrion Inc, H1 2017

Influenza A Virus, H3N2 Subtype Infections-Pipeline by FluGen Inc, H1 2017

Influenza A Virus, H3N2 Subtype Infections-Pipeline by Glide Pharmaceutical Technologies Ltd, H1 2017

Influenza A Virus, H3N2 Subtype Infections-Pipeline by ILiAD Biotechnologies LLC, H1 2017

Influenza A Virus, H3N2 Subtype Infections-Pipeline by Inovio Pharmaceuticals Inc, H1 2017

Influenza A Virus, H3N2 Subtype Infections-Pipeline by Johnson & Johnson, H1 2017

Influenza A Virus, H3N2 Subtype Infections-Pipeline by Medicago Inc, H1 2017

Influenza A Virus, H3N2 Subtype Infections-Pipeline by MedImmune LLC, H1 2017

Influenza A Virus, H3N2 Subtype Infections-Pipeline by Mucosis BV, H1 2017

Influenza A Virus, H3N2 Subtype Infections-Pipeline by NanoViricides Inc, H1 2017

Influenza A Virus, H3N2 Subtype Infections-Pipeline by Novavax Inc, H1 2017

Influenza A Virus, H3N2 Subtype Infections-Pipeline by OPKO Health Inc, H1 2017

Influenza A Virus, H3N2 Subtype Infections-Pipeline by Protein Sciences Corp, H1 2017

Influenza A Virus, H3N2 Subtype Infections-Pipeline by Sanofi Pasteur SA, H1 2017

Influenza A Virus, H3N2 Subtype Infections-Pipeline by Sarepta Therapeutics Inc, H1 2017

Influenza A Virus, H3N2 Subtype Infections-Pipeline by SK Chemicals Co Ltd, H1 2017

Influenza A Virus, H3N2 Subtype Infections-Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017

Influenza A Virus, H3N2 Subtype Infections-Pipeline by VBI Vaccines Inc, H1 2017

Influenza A Virus, H3N2 Subtype Infections-Pipeline by Visterra Inc, H1 2017

Influenza A Virus, H3N2 Subtype Infections-Pipeline by Zydus Cadila Healthcare Ltd, H1 2017

Influenza A Virus, H3N2 Subtype Infections-Dormant Projects, H1 2017

Influenza A Virus, H3N2 Subtype Infections-Discontinued Products, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AbbVie Inc, AIMM Therapeutics BV, Aphios Corp, BiondVax Pharmaceuticals Ltd, Celltrion Inc, FluGen Inc, Glide Pharmaceutical Technologies Ltd, ILiAD Biotechnologies LLC, Inovio Pharmaceuticals Inc, Johnson & Johnson, Medicago Inc, MedImmune LLC, Mucosis BV, NanoViricides Inc, Novavax Inc, OPKO Health Inc, Protein Sciences Corp, Sanofi Pasteur SA, Sarepta Therapeutics Inc, SK Chemicals Co Ltd, Takeda Pharmaceutical Company Ltd, VBI Vaccines Inc, Visterra Inc, Zydus Cadila Healthcare Ltd

Influenza A Virus, H3N2 Subtype Infections Therapeutic Products under Development, Key Players in Influenza A Virus, H3N2 Subtype Infections Therapeutics, Influenza A Virus, H3N2 Subtype Infections Pipeline Overview, Influenza A Virus, H3N2 Subtype Infections Pipeline, Influenza A Virus, H3N2 Subtype Infections Pipeline Assessment

select a license

Single User License
USD 2000 INR 129800
Site License
USD 4000 INR 259600
Corporate User License
USD 6000 INR 389400

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com